Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic

This study has been completed.
Sponsor:
Information provided by:
Hospital Pompeia
ClinicalTrials.gov Identifier:
NCT00440960
First received: February 26, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
  Purpose

The objective of the study was to establish which anesthetic procedure used during flexible bronchoscopy has the lowest index of complications.


Condition Intervention Phase
Lung Cancer
Drug: propofol
Drug: midazolam
Drug: alfentanil
Drug: lidocaine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Hospital Pompeia:

Detailed Description:

This prospective randomized study analyzed 80 patients that underwent flexible bronchoscopy. Patients were randomly assigned to four groups of 20 patients each according to the anesthetic combination used: 200 mg topical lidocaine (LID group); 200 mg topical lidocaine and 2 mg/kg propofol (PPF group); 200 mg topical lidocaine and 20 mcg/kg alfentanil (ALF group); or 200 mg topical lidocaine and 0.05 mg/kg midazolam (MID group). Scores were assigned to patients according to the different variables observed during the endoscopic procedure; the lower the score, the lower the complication index.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • The patients included in this study were referred to FBC for the investigation of bronchial carcinoma (diagnostic procedure).
  • Patients included in the study were classified as ASA I, II and II according to the anesthetic risk classification of the American Society of Anesthesiologists (ASA).

Exclusion Criteria:

  • ASA IV classification of anesthesiology risk
  • procedure that lasted longer than 15 minutes
  • indication of therapeutic bronchoscopy
  • cardiac arrhythmia and / or hypoxemia detected at admission.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00440960

Locations
Brazil
Hospital Pompeia
Caxias do Sul, RS, Brazil, 95010-005
Hospital Medianeira
Caxias do Sul, RS, Brazil, 95040-000
General Hospital of Universidade de Caxias do Sul
Caxias do Sul, RS, Brazil, 95070-560
Sponsors and Collaborators
Hospital Pompeia
Investigators
Principal Investigator: Andre GS Leite, PhD Brazilian Society of Thoracic Surgery
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00440960     History of Changes
Other Study ID Numbers: 0002.0.297.000-06
Study First Received: February 26, 2007
Last Updated: February 26, 2007
Health Authority: Brazil: Ministry of Health

Keywords provided by Hospital Pompeia:
alfentanil
anesthesia
bronchoscopy
lidocaine
midazolam
propofol.

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Alfentanil
Midazolam
Propofol
Anesthetics
Lidocaine
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Anesthetics, Intravenous
Anesthetics, General
Analgesics, Opioid
Adjuvants, Anesthesia
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Hypnotics and Sedatives
GABA Modulators

ClinicalTrials.gov processed this record on July 23, 2014